Efficacy and Safety of Cytotect®CP, Hyperimmune Anti-CMV IVIg as CMV Prophylaxis in Patients Developing Acute Grade II-IV GVHD After Allogeneic Hematopoietic Cell Transplantation. (CMV-GVHD)
Efficacy and Safety of Cytotect®CP, Hyperimmune Anti-CMV IVIg as CMV Prophylaxis in Patients Developing Acute Grade II-IV GVHD After Allogeneic Hematopoietic Cell Transplantation: A Prospective, Open-label, Phase II Study
Sponsor: Biotest
Terminated
Inclusion difficulties
Other terminated trials from Biotest
Other Cytomegalovirus Infections trials with similar outcome
A PHASE2 clinical study on Cytomegalovirus Infections, this trial is terminated or withdrawn. The trial is conducted by Biotest and has accumulated 6 data snapshots since 2022. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
6 versions recorded-
Oct 2025 — Present [monthly]
Terminated PHASE2
Status: Unknown → Terminated
-
Dec 2024 — Oct 2025 [monthly]
Unknown PHASE2
Status: Recruiting → Unknown
-
Sep 2024 — Dec 2024 [monthly]
Recruiting PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Dec 2022 — Jul 2024 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
▶ Show 1 earlier version
-
Jun 2022 — Dec 2022 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Biotest
- University Hospital, Lille
For direct contact, visit the study record on ClinicalTrials.gov .